HUE069150T2 - Piridazinilamino-származékok mint ALK5 inhibitorok - Google Patents

Piridazinilamino-származékok mint ALK5 inhibitorok

Info

Publication number
HUE069150T2
HUE069150T2 HUE21743186A HUE21743186A HUE069150T2 HU E069150 T2 HUE069150 T2 HU E069150T2 HU E21743186 A HUE21743186 A HU E21743186A HU E21743186 A HUE21743186 A HU E21743186A HU E069150 T2 HUE069150 T2 HU E069150T2
Authority
HU
Hungary
Prior art keywords
amino derivatives
alk5 inhibitors
pyridazinyl amino
pyridazinyl
alk5
Prior art date
Application number
HUE21743186A
Other languages
English (en)
Hungarian (hu)
Inventor
Daniela Pizzirani
Matteo Biagetti
Paolo Ronchi
Paolo Bruno
Sara Guariento
Barbara Bertani
Daniele Pala
Alessio Barilli
Original Assignee
Chiesi Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farm Spa filed Critical Chiesi Farm Spa
Publication of HUE069150T2 publication Critical patent/HUE069150T2/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/501Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Hydrogenated Pyridines (AREA)
HUE21743186A 2020-07-15 2021-07-14 Piridazinilamino-származékok mint ALK5 inhibitorok HUE069150T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP20185890 2020-07-15

Publications (1)

Publication Number Publication Date
HUE069150T2 true HUE069150T2 (hu) 2025-02-28

Family

ID=71620257

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE21743186A HUE069150T2 (hu) 2020-07-15 2021-07-14 Piridazinilamino-származékok mint ALK5 inhibitorok

Country Status (19)

Country Link
US (1) US12479826B2 (https=)
EP (1) EP4182308B1 (https=)
JP (1) JP7686741B2 (https=)
KR (1) KR20230051500A (https=)
CN (1) CN116096719B (https=)
AR (1) AR122986A1 (https=)
AU (1) AU2021307559A1 (https=)
BR (1) BR112023000588A8 (https=)
CA (1) CA3184990A1 (https=)
DK (1) DK4182308T3 (https=)
ES (1) ES2997111T3 (https=)
FI (1) FI4182308T3 (https=)
HR (1) HRP20241617T1 (https=)
HU (1) HUE069150T2 (https=)
MX (1) MX2023000521A (https=)
PL (1) PL4182308T3 (https=)
PT (1) PT4182308T (https=)
SI (1) SI4182308T1 (https=)
WO (1) WO2022013307A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7702205B2 (ja) * 2021-09-15 2025-07-03 株式会社東芝 新規アミン化合物、酸性ガス吸収剤、酸性ガスの除去方法及び酸性ガス除去
CN114957331A (zh) * 2022-04-22 2022-08-30 北京康辰药业股份有限公司 磷酸酯取代的环丙酰胺衍生喹唑啉类化合物的制备方法
WO2024180206A1 (en) 2023-03-02 2024-09-06 Chiesi Farmaceutici S.P.A. Pyridazinyl amino derivatives as alk5 inhibitors
WO2024180207A1 (en) 2023-03-02 2024-09-06 Chiesi Farmaceutici S.P.A. Pyridazinyl amino derivatives as alk5 inhibitors
KR20240159754A (ko) * 2023-04-28 2024-11-06 한국원자력의학원 N-메틸피페라진 에탄올 카바메이트(N-methylpiperazine ethanol carbamate) 구조를 포함하는 신규 화합물 및 이의 용도
WO2025132458A1 (en) 2023-12-18 2025-06-26 Chiesi Farmaceutici S.P.A. Pyridazinyl amino derivatives as alk5 inhibitors
WO2025132460A1 (en) 2023-12-18 2025-06-26 Chiesi Farmaceutici S.P.A. Pyridazinyl amino derivatives as alk5 inhibitors

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60001229T2 (de) 1999-04-09 2003-10-30 Smithkline Beecham Corp., Philadelphia Triarylimidazole
AR029803A1 (es) 2000-02-21 2003-07-16 Smithkline Beecham Plc Imidazoles sustituidos con piridilo y composiciones farmaceuticas que las comprenden
GB0007405D0 (en) 2000-03-27 2000-05-17 Smithkline Beecham Corp Compounds
EP1317450B1 (en) * 2000-09-15 2006-11-22 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
CA2423050A1 (en) 2000-09-20 2002-03-28 Ortho-Mcneil Pharmaceutical, Inc. Pyrazine derivatives as modulators of tyrosine kinases
AR039241A1 (es) 2002-04-04 2005-02-16 Biogen Inc Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
JP2006503043A (ja) * 2002-09-10 2006-01-26 サイオス インク. TGFβ阻害剤
AU2004278382B2 (en) * 2003-09-30 2008-09-18 Amgen Inc. Vanilloid receptor ligands and their use in treatments
BRPI0714409A2 (pt) 2006-07-14 2013-03-12 Novartis Ag derivados de pirimidina como inibidores de alk-5
ES2375425T3 (es) 2007-07-26 2012-02-29 Novartis Ag Compuestos org�?nicos.
BRPI0817434A2 (pt) 2007-10-17 2015-06-16 Novartis Ag Composto orgânicos
AR070127A1 (es) 2008-01-11 2010-03-17 Novartis Ag Pirrolo - pirimidinas y pirrolo -piridinas
MX2010007604A (es) 2008-01-11 2010-08-02 Novartis Ag Pirimidinas como inhibidores de cinasa.
US8343966B2 (en) 2008-01-11 2013-01-01 Novartis Ag Organic compounds
EA201001687A1 (ru) 2008-04-29 2011-06-30 Новартис Аг Производные имидазопиридина в качестве ингибиторов активиноподобной рецепторной киназы ( alk-4 или alk-5 )
CN102596200A (zh) * 2009-11-07 2012-07-18 默克专利有限公司 作为TGF-β受体激酶抑制剂的杂芳基氨基喹啉类
DK2731949T3 (en) 2011-07-13 2018-06-14 Tiumbio Co Ltd 2-PYRIDYL-SUBSTITUTED IMIDAZOLS AS ALK5 AND / OR ALK4 INHIBITORS
HRP20201384T1 (hr) * 2014-01-01 2020-11-27 Medivation Technologies Llc Spojevi i postupci njihove upotrebe
US20200247812A1 (en) * 2018-07-10 2020-08-06 Integral Biosciences Private Limited Heterocyclic compounds and methods of use

Also Published As

Publication number Publication date
DK4182308T3 (da) 2024-10-21
BR112023000588A2 (pt) 2023-01-31
ES2997111T3 (en) 2025-03-19
AR122986A1 (es) 2022-10-19
TW202216677A (zh) 2022-05-01
HRP20241617T1 (hr) 2025-01-31
CA3184990A1 (en) 2022-01-20
WO2022013307A1 (en) 2022-01-20
PT4182308T (pt) 2024-12-04
AU2021307559A1 (en) 2023-02-16
JP2023533849A (ja) 2023-08-04
KR20230051500A (ko) 2023-04-18
US12479826B2 (en) 2025-11-25
BR112023000588A8 (pt) 2023-05-09
JP7686741B2 (ja) 2025-06-02
EP4182308A1 (en) 2023-05-24
US20240018122A1 (en) 2024-01-18
CN116096719A (zh) 2023-05-09
SI4182308T1 (sl) 2025-04-30
FI4182308T3 (fi) 2024-12-07
PL4182308T3 (pl) 2025-01-07
EP4182308B1 (en) 2024-09-04
CN116096719B (zh) 2025-09-30
MX2023000521A (es) 2023-02-13

Similar Documents

Publication Publication Date Title
PT4182308T (pt) Derivados de piridazinil amino como inibidores de alk5
IL288405A (en) History of amino quinazolines as p2x3 inhibitors
IL308193A (en) RAS inhibitors
GB202001344D0 (en) Ras Inhibitors
IL326273A (en) RAS inhibitors
IL320513A (en) RAS inhibitors
IL285908A (en) Thiazole derivatives as inhibitors of protein secretion
PL4139286T3 (pl) Podstawione aminotiazole jako inhibitory dgkzeta do aktywacji immunologicznej
IL268625A (en) Amino pyrimidine compounds used as SSAO inhibitors
IL263739B (en) History of n-(converted-phenyl)-sulfonamide as kinase inhibitors
SG11202013016YA (en) Heterocyclic compounds as trk inhibitors
ZA202202245B (en) Quinoline derivatives as protein kinase inhibitors
IL284266A (en) History of (pyridin-2-yl)amine as an inhibitor of TGF-β in cell R1 (ALK5) for cancer treatment
ZA202000107B (en) Aminothiazole compounds as protein kinase inhibitors
GB2611484B (en) Hydrate inhibitors
IL289773A (en) Disubstituted amino triazoles are useful as chitinase inhibitors
HK40084408B (zh) 作为alk5抑制剂的哒嗪基氨基衍生物
CA3284342A1 (en) Pyridazinyl amino derivatives as alk5 inhibitors
IL310370A (en) Inhibitors of protein expression
ZA201908372B (en) Pyridoquinazoline derivatives useful as protein kinase inhibitors
ZA202201899B (en) Substituted amino triazoles useful as chitinase inhibitors
HK40059640A (en) Alk5 inhibitors for treating myelodysplastic syndrome
EP4182323C0 (en) PYRIDO-OXAZINE AMINO DERIVATIVES AS ALK5 INHIBITORS
EP4263533C0 (en) Erap inhibitors
IL313756A (en) Inhibitors of the sestrin-MAPK complex